Trial · NCT07052695
Mosunetuzumab for CLL MRD Clearance
NCT07052695, Phase 1, Phase 2, Recruiting, Inhye Ahn
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mosunetuzumab for CLL MRD Clearance. Trials, record NCT07052695. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07052695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mosunetuzumab for CLL MRD Clearance
- NCT number
- NCT07052695
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Inhye Ahn
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
- Interventions
- Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib
- First posted
- 2025-07-06
- Last updated
- 2025-12-15
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of undetectable bone marrow minimal residual disease | Up to 1 year | Undetectable bone marrow minimal residual disease (MRD) is defined by \< 1 CLL cell in 10,000 leukocytes (uMRD4) using an NGS-based assay at any time during C8 through C17 of mosunetuzumab. |
| Secondary | Safety of mosunetuzumab | Up to 30 days after the last dose of mosunetuzumab. | Adverse events |
| Secondary | Efficacy of mosunetuzumab | 3 years from the initiation of study therapy | Complete, partial, and overall responses based on the International Workshop on CLL guidelines, 3-year progression-free survival, 3-year time-to-next-treatment, 3-year treatment-free survival, 3-year overall survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07052695
GET https://conductscience.org/api/trials/v1/NCT07052695/registered